TECHNICAL NOTE
ORP/CSD-77-4
PLUTONIUM AIR INHALATION DOSE
(PAID)
A Code for Calculating Organ Doses Due to the Inhalation
and Ingestion of Radioactive Aerosols
U.S.Environmental Protection Agency
Office of Radiation Programs
Washington, D.C. 20460
-------
TECHNICAL NOTE
ORP/CSD-77-4
PLUTONIUM AIR INHALATION DOSE
(PAID)
A Code for calculating Organ Doses Due to the Inhalation
and Ingestion of Radioactive Aerosols
U.S. Environmental Protection Agency
Office of Radiation Programs
Washington, D.C. 20460
-------
TECHNICAL NOTE
ORP/CSD-77-4
PLUTONIUM AIR INHALATION DOSE
(PAID)
A Code for Calculating Organ Doses Due to the Inhalation
and Ingestion of Radioactive Aerosols
by
Robert E. Sullivan, Ph.D.
June 1977
Environmental Protection Agency
Office of Radiation Programs
Washington, D.C. 20460
-------
INTRODUCTION
This technical note describes a computer code, PAID, developed to
determine time dependent dose rates and doses from inhaled or ingested
radionuclides. The main purpose of this code is to determine the dose
rates and doses caused by the intake of transuranic nuclides and their
decay products.
The two primary modes leading to internal radiation exposure are
the inhalation and ingestion of radioactive materials. The estimation
of organ burden and exposure,* as well as of the resulting dose rates
and doses, due to uptake by these pathways is relatively complicated
and requires the adoption of mathematical models which depend on many
parameters. A computer code which implements the lung model described
by the ICRP Task Group on Lung Dynamics is presented below. This
model has been augmented to also include the dose due to the transfer
of radioactivity to other organs from ingested material's.
A. Inhalation
Industrial hygienists have recognized for many years that the
inhalation of an aerosol carrying radioactive nuclides was a potential
mechanism for damage to the respiratory tract as well as a possible
pathway for the translocation of inhaled radioactive material to other
reference organs. The complexity of the biological phenomena which
govern transmission and elimination of such material complicates the
consideration of potential health effects due to inhalation of
radioactive materials. Even a first order analysis of the process
must consider the factors enumerated below:
*The time integral of the burden has been referred to as the exposure
by the ICRP.
-------
(1) The fractional deposition of inhaled material in the
respiratory tract depends on properties of the aerosol - size and mass
distribution, chemical form and charge - as well as on the breathing
rate and such physiological characteristics of the lung as its surface
properties and configuration.
(2) The duration arid extent of the exposure depends on the
biological and physical mechanisms which transport the deposited
material and its decay product within the body. These include the
various clearance paths, the nuclide half-lives, the chemical form,
the solubility, and the degree of retention in each reference organ of
interest.
(3) The dose depends on the time integrals of the activity
of both parent and daughter in the organ, the organ mass, the emitted
energy of each nuclide, and the fraction of that energy absorbed by
the organ tissues. For alpha emitters, this absorbed fraction is
assumed to be unity. At present, the organ mass, breathing rate, and
clearance times in the PAID code correspond to those of a 30-year old
working male (1). Specific parameters are given in the text below.
The dose is calculated in rads - neither quality factors nor other
dose modifying factors are included in this program.
B. Ingestion
The ingestion of radioactive material represents another pathway
by which radioactivity may be transferred to bLood and, subsequently,
to other organs. While description of this pathway is simpler than
for inhalation, due to the direct deposition of the ingested material
into the gastrointestinal tract, treatment of the balance of the
-------
biological - physical processes involved suffers from the same
uncertainties in biological parameters as were discussed for the
inhalation model. The dose to the gastrointestinal tract itself is
not calculated by this program, nor is the normally negligible time
delay associated with transfer of the material through the stomach and
small intestine considered.
In the ingestion model, the critical transfer mechanism is the
absorption of radioactive material into the systemic blood from the
small intestine. Values for the fraction, f]_, of ingested
radioactivity transferred to blood have been studied in animals and,
to a very limited extent, in man but are still subject to large
uncertainties which strongly affect projected doses to the reference
internal organs, i.e., bone, liver, etc.
C. The Physical Model
Reasonable estimates of internal radiation doses due to
inhalation and ingestion require that a consistent model for both the
respiratory and gastrointestinal tracts be employed. While a large
amount of theoretical and experimental work on such models has been
done, the most widely accepted models have been those developed by
members of the respective International Commission on Radiological
Protection (ICRP) working groups.
The ICRP Task Group on Lung Dynamics (TGLD) has proposed a model
for the respiratory tract which has been well documented (2).
Parameters suggested for use in the model have been extensively
reviewed and, to some extent, improved in later ICRP publications (3).
Details of this model are given by Morrow and the revised parameters
-------
have been collected by the ICRP in reference (3) . Therefore, only a
brief outline of the model is presented here. The ICRP TGLD proposed
model comprises three major compartments: the nasopharyngeal, the
tracheobronchial and the pulmonary, as shown in Figure I.
Each of these major compartments is divided into subcompartments,
corresponding to various transfer mechanisms, which are treated as
essentially independent processes. In addition, the associated lymph
nodes are appended to the pulmonary compartment in one of the transfer
chains. Direct deposition through inhalation is only to the three
major compartments with the fractional deposition in each a function
of the aerosol properties. Subsequent transfer and/or clearance is
governed by the parameters specified for each subcompartment, as shown
in Table I, taken from reference (3). Pathways are indicated in
Figure I.
-------
FIGURE 1
R
E
F
E
R
E
N
C
E
O
R
G
A
N
B
L
O
O
D
NASOPHARYNGEAL
I (N-P)
I
(b)
?D4
tTRACHEOBRONCHIAL I
, (T« I
s
T
O
M
A
C
H
D^ is the total aerosol inhaled; D2 is the aerosol in the exhaled air;
DS» 04, and DC are the amounts deposited in the nasopharyngeal,
tracheobronchial, and pulmonary lung' respectively. The letters (a)
through (i) indicate the process which translocates material from one
compartment to another. Values for these parameters are listed in
Table I.
-------
Table I
Biological Half-lives in Days and Transfer
Fractions for Use with TGLD Clearance Model
Recrion
N-P
T-B
P
L
Pathway
(a)
(b)
(c)
-------
An ICRP gastrointestinal tract model has been documented
The model comprises a four compartment tract consisting of the
stomach, small intestine and lower and upper large intestine. The
times involved in the passage of material through the stomach and
small intestine (the only compartment from which transfer into the
blood occurs) are negligible compared to the half-lives associated
with most class Y compounds and are neglected when considering doses
due to ingestion.
Although both these models are described exhaustively in words,
neither of the ICRP groups has given mathematical descriptions for the
various processes involved. This lack has led to some confusion in
attempting to calculate doses and effects using the models. For the
present treatment, several of the previous analyses, (5,6,7), have
been reviewed and discrepancies or omissions in their equations
compared with the "official" verbal descriptions of the models. While
some ambiguities may remain, the present treatment has attempted to
reconcile differences between the ICRP descriptions and these earlier
codes. Several features, not common to all previous codes, which have
been incorporated into PAID include: (1) explicit calculation of the
dose rates and doses due to both parent and daughter products, (2)
inclusion of the dose to the tracheobronchial region due to the
clearance of material deposited in the pulmonary region, (3)
calculation of the dose from material permanently retained in the
lymph nodes, (4) separate calculation (and printout) of the percentage
of the total dose to a reference organ due to absorption from the
gastrointestinal tract for both parent and daughter. This latter
-------
feature allows various values of f^_ to be substituted without
repeating the whole calculation.
D. The Mathematical Model
The PAID code used by the Environmental Protection Agency (EPA)
corresponds to descriptions of the physiological processes as
contemplated by the originating ICRP working group. In addition, an
attempt has been made to keep the resulting mathematical relationships
as simple and understandable as possible. To this end, the
respiratory and gastrointestinal tract models have been coupled as
outlined below:
The ICRP TGLD model implicitly assumes that the physiological
processes associated with each subcompartment operate independently.
The simplest mathematical treatment of the model is to consider a
chain consisting of up to three components for both parent and
daughter. The first component in each chain represents a lung
subcompartment, the second either the reference organ or the lymph
nodes, and the last the reference organ for the lung-lymph node
pathway. For the ingestion pathway only one component - representing
the reference organ - is used since the dose to the gastrointestinal
tract is not calculated. A general differential equation governing
the behavior of each series - connected component in a chain of
arbitrary length may be written as:
(1)
qn (t) = Sn(t) - Xnqn(t)
-------
where qn(t) = the organ or subcompartment burden (curies)
for the nth subcompartment
Sn(t) = the source term for the nth compartment (curies/yr)
Xn = the total, or effective, decay constant for the
radionuclide in the nth compartment (yr-1)
The source term will vary, depending on the position of the
compartment in the chain and whether the parent or daughter is under
consideration. Direct deposition within the lung is through
inhalation of the parent and is into the major compartments;
nasopharyngeal, tracheobronchial and pulmonary. These major
compartments are further divided into subcompartments and their
associated pathways; (a) through (i) listed in Table I.
Consider first the equations for the organ burden due to the
parent, Sp. The source term in the first compartment (subcompartment)
of the lung will be:
Sp (t) " IcDkfl
where D^ is the deposition fraction for the major compartment as shown
in (2); f^ is the fraction of D^ translocated through pathway it Table
I and Ic is the rate (curies/year) of constant chronic intake based on
the breathing rate given in Table II. Thus, IG = (Breathing Rate) x
(Air Concentration). Mathematically, any acute intake is presumed to
be present at time zero, i.e.,
q(t = 0) = IDf (2)
-------
where the subscript A denotes acute and q (t=0) is inserted as a
boundary condition.
Table II
Breathing Rate - Male Adult ICRP Report f23 (ICRP 1975)
Minute Volume Duration
(liters/minute) (hours/day)
Light Activity 20.0 16
Resting 7.5 8
Average Daily Intake = 2.3 x 10* liters.
For ingestion, the only component is the reference organ and the
source here is:
s1 (t) = ic
p c
where, again, 1 is the annual intake in curies for constant,
continuous ingestion. Any acute intake is, again, treated as a
boundary condition.
For succeeding components in the chain, the only source (for
parent radionuclides is material transmitted from the preceeding
compartment. All organs (subcompartments) inferior in position to the
first are presumed to have no initial radionuclide content, q(o) = 0.
Therefore, for all subsequent organs
(3)
_ fn b, CTn-l
~ P P q
10
-------
where n-1 refers to the preceeding member of the chain and Xp is the
biological decay constant of the parent. It is obvious, from the last
equation, that each equation in the chain is coupled to all preceeding
equations through the source term.
Coupled equations of this type are most readily solved by using
Laplace transforms. (8) Application of a Laplace transform to Equation
1 yields, using s as the transformed variable,
sqn(s) - q = Sn(s) - Xnq(s) (4)
o
where, to simplify the notation ~^" is written as q(s). Then,
n
qn(s) = S"(s) + q0
8(8 + An) (S + Xn)
and qn is the initial burden, due to acute intake. The initial organ
o
burden for all organs inferior to the first is set equal to zero.
Furthermore, the source terms for the first organ (or subcompartment)
are constant and their transforms will be:
. (5)
for inhalation or
(6)
for ingestion. Again Ic represents a constant, continuous intake
(Ci/yr) . The general equation then becomes, in transform space,
1, . I D^f1 ^ qj (7)
q (s) = c k p + °
P s(s + Xp-) (s + Al)
11
-------
for the first component of the chain, where q1, if present, is given by
equation 2. Using the transformed Equation 7 as the source in
Equation 3, the equation for the second member of the chain is seen to
be
bxlf2
(s + X2)
I DJ:1 1
c k p + qo
s(s + Xl) (s + Xl)
(8)
from which it is obvious that the equation for each succeeding
component differs only by an additional factor (s + X) and, of course,
n-1
by modification of the coefficient by the terms fn and X
, • the
translocation fraction to the next organ and the biological decay
constant of the previous, respectively. The general equation for the
nth organ or subcompartment may then be written as:
n
n i
1 = 1
ri b i-1
-P xp
1
c* k + o
r n . I f n . T
s In (S + x1) Ln (s + Xp)
(9)
where X° is defined as 1 and the first term corresponds to the
continuous intake case and the last to the acute intake case.
12
-------
The governing equations for the daughter product are similar to
those for the parent with appropriate changes in the source terms.
One question, which has not been addressed by the ICRP, is whether the
decay product remains in the parental chain, or whether the total
decay product in a given compartment should be reapportioned according
to its transfer fractions, in the PAID code, the former assumption
has been made, i.e., the daughter formed by decay of the parent in a
given clearance pathway is assumed to continue to clear through that
pathway although governed by its own physical parameters. For the
first component in the chain, the only source is decay of the parent
and equation (1) becomes
(t) = S» (t) - X|jqj(t) (10)
where the symbols are as for the parent with D denoting the daughter
product. Taking the transform of this, noting that S1 = rXDq1(t)
and substituting q*(s) from equation 7,
s(s + xh (s + X^) (s + X ) (s
(11)
where ^ is the physical decay constant.
For the second, and succeeding components, the source term
comprises two parts; that describing the decay of the parent in the
13
-------
same compartment and that describing translocation of the daughter
from the preceeding compartment, thus
(12)
q(t) =
and
s + X
D
(13)
Substituting the q2 (sy and the q1 (s) derived above, the second
P D
compartment daughter burden becomes
b12
8(8 + X£)(S + X*)(8 + XD)
(s + X*) (s
(s +
_ (14)
s(s + \b (s + xi) (s + X2) (s + A (s + Xj) (s + XD)
• For the third compartment, the governing equation is the same but the
source term becomes
(15)
SD(t> =
14.
-------
from whence, again using the q*(s) and q2 (s) obtained previously
a +
sts. + X*> (s + X2) (s + X*) (s + XQ) (s + X*) (s + Xp) (s + XpS (s +
A f B
A ^ B
s(s + xi (s + xi (s + x) (s + xi (s + \i (s + x5 (s + \5 (s +
s(8 + X) (s +X (s t^) (s +X) (S + x) (s +X} (s + X} (s
where a, 3, A, B, C, and D are given in Appendix I.
From both the parent and daughter derivations it is apparent
that, although these equations may readily be extended to describe
additional compartments and/or decay products, the resulting equations
rapidly become quite prolix. As presently constituted, the PAID code
comprises the first three compartments for both parent and daughter
since these are sufficient to handle the problem under consideration.
However, the transformed differential equations are all similar,
regardless of the number of compartments involved, i.e., the time (s)
dependent terms are of the form
15
-------
(s-k l fs-k 1 fsHTi {17)
\C> J^.-i J \o K.~J ... (5 Jv_|
where k-^, k2,...km are constants which may be positive, negative or
zero. When kj.is zero, the terms assume the form
sfs-k 1 1 f
-------
quadratic or higher order terms, applying the expansion to equations
of the form (17) yields a general solution:
,-1 - (21)
1
g(s)
M
- £
m=l
for both the acute case, corresponding to the equation (17) and the
chronic case, equation (18) . Solutions to equation (18) , as
mentioned, are also general solutions for the exposure, Q(T) , for the
case of acute intake.
Inverse transforms for equations containing repeated linear
factors, while somewhat more tedious to calculate, are still
straightforward (8) . The general solution for terms having the form
of equation (20) for the exposure, may be found by noting that (20)
may be rewritten as:
4>(s)
(22)
(s -
where the inverse transform corresponding to the rth power term is:
(23)
n
F(t) = £
r=0
n-r
(n-r)!
tr exp
These solutions may, perhaps, be more readily verified by conventional
integration of the burden equation.
17
-------
One advantage of Laplace transforms is that an unlimited number
of subcompartments, in series, may easily be treated, in a computer
program loop, by addition of the appropriate term to the solution of
the previous subcompartment. In addition, inverse transforms for the
equations for Class D and Class W compounds, which contain terms in
the denominator of the form (s - k)r are also found using the formulae
in equation (23). Thus, it is possible, if the required parameters
are known, to solve for transfer from the lung to a first reference
organ (i.e. liver, bone, etc.) followed by subsequent translocation to
another reference organ. Since the biological half-lives currently
utilized with ICRP models are the net result of such processes as
apposition and resorption, this feature is not used in the current
version of the PAID code. However, use of this feature would provide
a means of testing more general models of intercompartmental transfer
than those proposed by the ICRP and, for this reason, may be of
interest to investigators studying a range of metabolic problems.
For the lung, the dose is defined here as the average dose to a
pulmonary compartment of 570 grams which is the mass of the pulmonary
lung, including capillary blood, ICRP #23 (1). This dose may be used
»
to estimate the risk of lung cancer. The dose rate, D, and dose, D,
are defined in terms of the organ burden, q, and exposure, Q, in uCi
and uCi days, respectively:
D(t) = 51.2 e q(t) rad per day
m
and
18
-------
D(t) = 51.2 _£_ Q(t) rad
m
where
e = the absorbed energy (MeV) .per disintegration
for a particular isotope and organ pair.
m ,:= the mass of the organ (grams)
Finally, health effects may be estimated by multiplying the dose
to each organ by the number of effects expected per unit dose.
E. Computer Program
As previously stated, only the first three compartments for
parent and daughter radionuclides, both of the same class, are
presently contained in the PAID code. The complete solutions for
these cases, obtained by applying formulae 21 and 23 to the
transformed equations derived above, are presented in Appendix'I.
Appendix .III is a listing of the code for Class Y compounds and
Appendix II contains the input/output for a sample problem. The
listing for Class W would be identical but for substituting the
appropriate parameters from Table I.
To simplify the coding as much as possible, the procedure
followed is to obtain the solution for each subcompartment in a chain.
When the solutions for all chains are found, the subcompartments are
then summed over to obtain total dose rates and doses for each major
compartment or reference organ.
For ingestion, where the delay in the stomach and small intestine
is neglected there is only one compartment, the reference organ.
19
-------
Finally, two additional modifiers for the equations must be
considered. First, for material which is transferred through the
gastrointestinal tract, the additional fraction f^_ (transfer from
small intestine to blood) must be used as a multiplier for organs
inferior to the small intestine. Second, for material transferred
through the systemic blood, the fraction f^ (the fraction from blood
to reference organ) must be incorporated into the product of the
transmission fractions. These parameters are automatically inserted
by the program.
Summary
The equations in Appendix I have been programmed for the IBM 360
computer in FORTRAN IV. Either the acute or constant continuous
intake cases may be solved for both parent and daughter dose rate and
dose. Built-in controls allow selection of the inhalation or
ingestion case. The parameters for the ICRP model, shown in Table I,
are built into the code. Only the reference organ parameters, i.e.,
fractional transmissions and biological half-lives, must be supplied
as input. The assumption for the lymph nodes is that material not
translocated to the reference organ remains in place and is lost only
by radioactive decay. Explicit dose rates and doses to the
tracheobronchial lung due to clearance of material from the pulmonary
lung are printed out separately for both parent and daughter. The
percentage of total dose due to transfer of material through the
gastrointestinal tract is given for inhalation cases. General input
instructions for the code are given in Appendix II.
20
-------
REFERENCES
1. International Commission on Radiological Protection (ICRP) ,
Publication 23, Pergamon Press, New York, 1975
2. International Commission on Radiological Protection (ICRP) Task
Group on Lung Dynamics. "Deposition and Retention Models for
Internal Dosimetry of the Human Respiratory Tract", Health
Physics, 1966.
3. International Commission on Radiological Protection (ICRP) ,
Publication 19, Pergamon Press, New York.
1. International Commission on Radiological Protection (ICRP) ,
Publication 2, 1959, Pergamon Press, New York
5. Brain, J. D. and Volber, P. A. "Models of Lung Retention Based
on ICRP Task Group Report," Arch. Environ. Health, v. 28,
January, 1974.
6. Kotrappa, P. "Calculation of the Burden and Dose to the
Respiratory Tract from the Continuous Inhalation of a Radioactive
Aerosol," Health Physics, v. 17, pp. 429-432, 1969.
7. Houston, J.R., Strenger, D. L., and Watson, E. C. "DACRIN,"
BNWL-B-389, Battelle Pacific Northwest Laboratories, December,
1974.
8. Churchill, Ruel, V., 1944. Modern Operational Mathematics in
Engineering, McGraw-Hill, New York.
9. International Commission on Radiological Protection (ICRP)
Publication 10A, Pergamon Press, New York, 1969.
21
-------
APPENDIX I
This Appendix gives the inverse transforms (time dependent
solutions) of both parent and daughter for the first three
compartments. The differential equations are derived in the text and
the solutions found using the formula of equation (21) . The
solutions, as shown, are for the organ burden q(t), since these
comprise the time dependent portion of the dose rate, equation (24) .
The exposures, Q(T), are not given since the integral of all terms in
q (t) is either of the form
or
Q(T) =
Q(T) =
_L f
k Jc
-L f(
k j
dt =
exp (-Xt) dt =
1 - exp (-Xt)
kX
both of which are integrable by inspection.
for the parent compartments are:
The organ burdens, q(t)
(1)
q-'-(t) =
P
exp (-Xpt)
exp (-Xpt)
(2)
qp(t)
P P
exp (-Xt)
1 2
exp (-
P P P A k
exp
(-Xp-4-X2)
P
22
-------
(3)
p p p p p <
I D,
c k
IcDk exp (-X^t)
A1*2*3
APAPAP
IcDk axp (-Xpt)
exp (-At)
exp (-Xpt)
,2. .-
IADk exp (-
-
and for the daughter compartments:
(D
I D f exp (-At;
+ r^;——,—:; +
PD
23
-------
(2)
= A
exp <-
exp (-
2
exp (-Xt)
exp <-xt)
exp (-
exp (~
exp (-;
exp (-Xt)
exp (-xt)
exp (-
exp (-Xjt)
24
-------
(3)
qjj(t) -a 1 A ^ (-X
xp-x2x3x3 -xpx-xj+x2) (
exp (-X2t)
* +
2 z 1 * 3 2 3 3
~XP (~Xp+Xp) (~Xp+Xp) ^~Xp+XD) ~XP
3
exp <-X«t) ft
u + P
, 2 .
exp (-X_t)
f-l -t-1 W-l 4-1 W-l 40t ^ -i
\ ApTApV ^ ApTAp./ ^ Ap AT)-' A
exp (-X3t) A
Nil "JO 1^
(-X +X ) (-X +X ) (-X +X )
b,2,3 , .1 . b.
D 2 exp ^~Xpt' X]
i«
exp (-Xpt)
(-x|+xj) (-Xp+x2) (-x3+x3)
1
exp (-Xpt)
19 1 ^ 1 ^
C-xJ+xp (-xj+x^) (-xj+x^)
exp (-Xpt)
5-51 T 9 "} ^
J(-x|+xp(-xJ+Xp)(-x|+xp
" bX2f3
n 9
L> Z ^
XXX2X2X3
_ApApADAD
£f3 exp (-X2t)
(-xj+x2)(-xj+x3)
+x)(-x2+x3)
bX2f3 exp (-X2t)
b.2,3 , ,3.
Xf exp (-X
+ B
bX2f3 exp (-
(-Xp+X2)(-Xp+A3)
-x3(-x3+xj)(-x3+x2)(-x3+x2)
bX2f3 exp (-X2t)
(-x2+xj)(-x2+x2)(-x2+x3)
b.2,3- . ,2
Xf exp (-X
f exp (-Xt)
(-X2+X2) (-X2+X3)
(-x3+xj)(-x3+x2)(-x3+x2)
25
-------
X'f
D2
b.2,3 t .1 N
XDf2 exp (-XDt)
b.2-3
, ,
exp (-
exp (-Xpt)
exp (-Apt)
exp -
a =
•
r. b,2
and Xn is the decay constant for the parent or daughter in the
P,D
nth compartment.
26
-------
APPENDIX II
Contained below is a listing of the FORTRAN IV PAID code. In
general, as described in the text, the code yields dose rates and
doses to the lung, using the ICRP TGLD model, and any selected
reference organ. The printout of a sample case is included.
A description of the input parameters, format, and options
available is given below. An attempt has been made to keep the input
as simple as possible and the program will run multiple cases if
another set of input data is added. All of the data pertaining to the
lung are set within the code based on reference (3).
Card 1
One title card for identification of the
problem.
20 A*
Card 2
NTT
IHG -1/0/+1
IFLAG -1/0/+1
Number of times for which solutions 110
are desired.
(Ingestion/Inhalation/Inhalation) 110
case
(Omit/Print/Print) To supress output 110
for lung compartments. Used for inhalation
cases only.
Card 3
LRP
LBP
F1PR
F2PPR
EPSPL
EPSPR
Physical half-life (years) of the parent.
Biological half-life (years) of the
parent.
GI Tract to blood (f-^) fraction for
the parent.
i
Blood to reference organ (±2) fraction
for the parent.
Average energy (meV) for the parent
decay in the lung.
Average energy (meV) for the parent
decay in the reference organ.
E12.5
E12.5
E12. 5
El2. 5
E12.5
E12.5
27
-------
Card 4
(Same as card 3 but for daughter instead
of parent.
Card 5
TIN (I) Times for which solutions are required 6E12.5
(years) .
Card 6
IA The acute intake (Ci) E12.5
1C The chronic intake (Ci/yr) E12.5
OTA3 The deposition fractions E12.5
UTA4 for the N-P, T-B and E12.5
UTA5 P compartment respectively El 2.5
0RGMR Reference organ mass (g) . E12.5
Return to Card 1 for the next case.
28
-------
SAMPLE CASE
PU-239/U-235 AFPOSOL CONC. 1.0 (FCI/CUBIC METER AMAO*0.05 R.O.=LIVER
ACUTE
INTAKE (CII
0.0
PHYSICAL
HALF-LIFE
(YEARS)
2.44000D+Ot
PHYSICAL
HALF-LTFF
(YEARS)
7.100000*06
CHRONIC
INTAKE (CI/YR)
8.32770F-12
FOR THF PARENT —
BIOLOGICAL
HALF-LIFE
(YEARS)
4.00000D+01
FOR THE DAUGHTSR--
BIOLOGICAL
HALF-LIFE
(YEARS)
2.7*0000-01
N - P
DEPOSITION
1. 000005-03
TRANSMISSION
FRACTION
(GIT-BLODD)
l.OOOOOE-04
TRANSMISSION
FRACTION
(GIT-BLOOD)
l.OOOOOE-02
T - B
DEPOS-ITION
8.00000E-02
TRANSMISSION
FRACTION
(BLOOD-R.O. )
4. 50000E-01
TRANSMISSION
FRACTION
(BLOOO-R.O. )
1. 10000E-01
P
DEPOSITION
5.900006-01
AVERAGE
ENERGY-LUNG
IMEV)
5.15000E+00
AVERAGE
ENERGY-LUNG
IMEV)
4.40000E+00
REFERENCE
ORGAN MASS (G)
1.80000E+03
AVERAGE
ENERGY-R.O.
(MEV)
5.15000E*00
AVERAGE
ENERGY-R.O.
(MEV)
4.400006+00
THE FOLLOWING C#S* IS FOR UPTAKE DUE TO INHALATION.
AT TIMP 1.00 YEARSt DDSE RATES (RAOS/YR) AND DOSES (RADS) ARE—
FOP THF. NASOPHYRINGIAL COMPARTMENT
PARENT
DOSE RATF
3.93937E-08
PARENT
DOSE
3.93312F-08
DAUGHTER
DOSE RATF
5.21315E-18
DAUGHTER
DOSE
5.19660E-18
TOTAL
DOSE RATE
3.93937E-08
TOTAL
DOSF
3.93312E-08
FOP THE TPACHfOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
1.26092E-06
PARENT
DOSS
1.25992E-06
FOP TH«= TRACHEOBR3NCHIAL COMPARTMENT
PARENT
DOSE RATE
2.57801E-05
FOR THE PULMONARY
PARENT
DOSE RATE
3.92202E-0*
PARENT
DOSE
2.23527E-05
COMPARTMENT
PARENT
DOSE-
2.13152E-04
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEAPANCE
DAUGHTER
DOSE RATF.
2.85821E-13
DAUGHTER
DOSE RATE
1.49313E-11
DAUGHTER
DOSE
8.32796E-17
TOTAL
DOSE RATE
1.26092E-06
TOTAL
DOSE
1.25992F-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
1.07341E-13
DAUGHTER
DOSE
5.41047E-12
TOTAL
DOSE RATE
2.57801E-05
TOTAL
DOSE RATE
3.92202E-04
TOTAL
DOSE
2.23527E-05
TOTAL
OOSE
2.13152E-04
FOR THE LYMPH NODES, TRANSMITTED FRACTION
PARENT PARENT DAUGHTER
DAUGHTER
TOTAL
TOTAL
-------
DOSE RATE DOSE
8.40843E-04 2.98284E-04
DOSE RATE
4.52451E-U
DOSE
1.19691E-11
DOSE RATE
8.40843E-04
FOR THE LYMPH NODESt RETAINED FRACTION
PARENT PARENT
DOSE RATE DOSE
1.01809E-04 3.53171E-05
FOR THE REFERENCE ORGANf PARENTHESES
PARENT PARENT
DOSE RATE DOSE ( 0.58)
1.71491E-06 5.96853E-07
AT TINE 5.00 YEARS, DOSE RATES (RADS/YRJ
FOR THE NASOPHYRINGIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
3.93937E-08 1.96906E-07
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
1.26092E-06 6.30359E-06
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DOSE RATE" DOSE
3.54360E-05 1.50893E-04
FOR THE PULMONARY COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
9.07419E-04 3.13829E-03
DAUGHTER
DOSE RATE
5.36360E-12
INDICATE PERCENT
DAUGHTER
DOSE RATE
3.47688E-14
AND DOSES (RAOSI
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
2. 19222E-12
DAUGHTER
DOSE RATE
1.16653E-10
DAUGHTER
DOSE
1.44634E-12
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 1.66)
1.04372E-14
ARE--
DAUGHTER
DOSE
2.60492E-17
DAUGHTER
DOSE
4.16927E-16
TOT At
DOSE RATE
1.01809E-04
TRACT
TOTAL
DOSE RATE
1.7149 1E-06
TOTAL
DOSE RATE
3.93937E-08
TOTAL
DOSE RATE
1.2609 2E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
5.38419E-12
DAUGHTER
DOSE
2.85694E-10
TOTAL
DOSE RATE
3.54360E-05
TOTAL
DOSE RATE
9.07419E-04
FOR THE LYMPH NODES* TRANSMITTED FRACTION
PARENT PARENT
DOSE RATE DOSE
8.67108E-03 1.92681E-02
DAUGHTER
DOSE RATE
2.00876E-09
DAUGHTER
DOSE
3.29601E-09
TOTAL
DOSE RATE
8.67108E-03
FOR THE LYMPH NODES, RETAINED FRACTION
PARENT PARENT
DOSE RATE DOSE
U50491E-03 2.93922E-03
DAUGHTER
DOSE RATE
3.15821E-10
DAUGHTER
DOSE
4.76682E-10
TOTAL
DOSE RATE
1.504916-03
DOSE
2.98284E-04
TOTAL
DOSE
3.53171E-05
TOTAL
DOSE I 0.58)
5.96853E-07
TOTAL
DOSE
1.96906E-07
TOTAL
DOSE
6.30359E-06
TOTAL
DOSE
U50893E-04
TOTAL
DOSE
3.13829E-03
TOTAL
DOSE
1.92681E-02
TOTAL
DOSE
2.93922E-03
-------
FOR THE REFERENCE ORGAN, PARENTHESES INDICATE PERCENT OF TOTAL DOSE VIA 61 TRACT
PARENT
DOSE RATE
3.68285E-05
IMF 10.00 YEARS
PARENT
DOSE < 0.16)
6.43889E-05
, DOSE RATES (RADS/YR1
DAUGHTER
DOSE RATE
1.27893E-12
AND DOSES (RAOS)
DAUGHTER
DOSE ( 0.68)
2.09867E-12
ARE-
TOTAL
DOSE RATE
3.68285E-05
T
FOP THE NASOPHYRINGIAL COMPARTMENT
PARENT
DOSE RATE
3.93937E-08
PARENT
DOSE
3,938751:- 07
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE
5.211 50E-17
TOTAL
DOSE RATE
3.93937E-08
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSP RATE
1. 26092 E-06
PARENT
DOSE
1.26082E-05
FOP THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
3.67897E-05
PARENT
00 SE
3.32751E-04
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
2. 43097 E- 12
DAUGHTER
DOSE
8.33987E-16
TOTAL
OOSE RATE
1.26092E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
1.87231E-11
TOTAL
DOSE RATE
3.67897E-05
FOR THE PULMONARY COMPARTMENT
PARENT
DOSE RATE
9.796496-04
FOR THE LYMPH
PARENT
DOSE RATE
1.42583E-02
FOR THE LYMPH
PARENT
DOSE RATE
3.80168E-03
PARENT
DOSE
7.92503E-03
DAUGHTER
DOSE RATE
1.56071E-10
DAUGHTER
DOSE
9.95832E-10
TOTAL
DOSE RATE
9.79649E-04
NODES, TRANSMITTED FRACTION
PARENT
DOSE
7.89133E-02
DAUGHTER
DOSE RATE.
5.30992E-09
DAUGHTER
DOSE
2.20530E-08
TOTAL
DOSE RATE
1.42583E-02
NODES, RETAINED FRACTION
PARENT
DOSE
1.61402E-02
FOR THE REFERENCE ORGAN, PARENTHESES
PARENT
DOSE RATE
1.16482E-04
PARENT
DOSE ( 0.10)
4.38825E-04
DAUGHTER
DOSE RATE
1.20973E-09
INDICATE PERCENT
DAUGHTER
DOSE RATE
4.17767E-12
DAUGHTER
OOSE
4.14608E-09
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 0.37)
1.54630E-11
TOTAL
DOSE RATE
3.B0168E-03
TRACT
TOTAL
DOSE RATE
1.16482E-04
TOTAL
OOSE ( 0.16)
6.43889E-05
TOTAL
DOSE
3.93875E-07
TOTAL
DOSE
1.26082E-05
TOTAL
DOSE
3.32751E-04
TOTAL
DOSE
7.92503E-03
TOTAL
DOSE
7.89133E-02
TOTAL
DOSE
1.61402E-02
TOTAL
DOSE ( 0.10)
4.38825E-04
AT TIME 15.00 YEARS, DOSE RATES (RAOS/YRI AND DOSES (RADS1 ARE—
-------
FOR THE NASOPHYRINGIAL' COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
3.93937E-08 5.90B44E-07
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
1.26092E-06 1.89127E-05
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
3.68976E-05 5.17073E-04
FOR THE PULMONARY COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
9.85406E-04 1. 2 8432 E- 02
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
3.03486E-12
DAUGHTER
DOSE RATE
1.61614E-10
DAUGHTER
DOSE
7.B1807E-17
DAUGHTER
DOSE
1.25105E-15
TOTAL
DOSE RATE
3.93937E-08
TOTAL
DOSE RATE
1.26092E-06
TOTAL
DOSE
5.90844E-07
TOTAL
DOSE
1.89127E-05
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
3.37230E-11
DAUGHTER
DOSE
1.79460E-09
TOTAL
DOSE RATE
3.68976E-05
TOTAL
DOSE RATE
9.85406E-04
TOTAL
DOSE
5. 17073E-04
TOTAL
DOSE
1.28432E-02
FOR THE LYMPH NODESt TRANSMITTED FRACTION
PARENT PARENT
DOSE RATE DOSE
1.60B59E-02 1.55668E-01
DAUGHTER
DOSE RATE
7. 14067E-09
DAUGHTER
DOSE
5.37807E-08
TOTAL
DOSE RATE
1.60859E-02
TOTAL
DOSE
1.5566BE-01
FOR THE LYMPH NODESt RETAINED FRACTION
PARENT PARENT
DOSE RATE DOSE
6.16126E-03 4.10425E-02
FOR THE REFERENCE ORGAN, PARENTHESES
PARENT PARENT
DOSE RATE DOSE 1 0.08)
2.05681E-04 1.24387E-03
DAUGHTER
DOSE RATE
2.30476E-09
INDICATE PERCENT
DAUGHTER
DOSE RATE
7.29602E-12
DAUGHTER
DOSE
1.28925E-08
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 0.26)
4.41827E-11
TOTAL
DOSE RATE
6.16126E-03
TRACT
TOTAL
DOSE RATE
2.05681E-04
TOTAL
DOSE
4. 10425E-02
TOTAL
DOSE 1 0.08)
1.24387E-03
AT TIME 20.00 YEARS, DOSE RATES (RADS/YR) AND DOSES (RADS) ARE—
FOR THE NASOPHYRINGIAL COMPARTMENT
PARENT
DOSE RATE
3.93937E-08
PARENT
DOSE
7.87812E-07
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE
1.04247E-16
TOTAL
DOSE RATE
3.93937E-08
TOTAL
DOSE
7.87812E-07
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DAUGHTER
DAUGHTER
TOTAL
TOTAL
-------
DOSE RATE DOSE
1.26092E-06 2. 521 736-05
FOR THE TRACHEOBRONCH1AL COMPARTMENT
PARENT PARENT
OOSE RATE DOSE
3.69062E-05 7.01590E-04
FOR THE PULMONARY COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
9.85865E-0* 1.77718E-02
OOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
3.04673E-12
DAUGHTER
DOSE RATE
1.62248E-10
DOSE
1.66811E-15
DOSE RATE
1.26092E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
4.89372E-11
DAUGHTER
DOSE
2.60480E-09
TOTAL
DOSE RATE
3.69062E-05
TOTAL
DOSE RATE
9.85865E-04
FOR THE LYMPH NODES, TRANSMITTED FRACTION
PARENT PARENT
DOSE RATE DOSE
1.66217E-02 2.37709E-01
DAUGHTER
DOSE RATE
7.90025E-09
DAUGHTER
DOSE
9.16817E-08
TOTAL
DOSE RATE
1.6621 8E-02
FOR THE LYMPH NODES, RETAINED FRACTION
PARENT PARENT
DOSE RATE DOSE
8.52554E-03 7.77592E-02
FOR THE REFERENCE ORGAN, PARENTHESES
PARENT PARENT
DOSE RATE DOSE ( 0.07)
2.92287E-04 2.49088E-03
AT TIME 30.00 YEARS, DOSE RATES IRADS/YR)
FOR THE NASOPHYRINGIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
3.93937E-08 1.18175E-06
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
1.26092E-06 3.78265E-05
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT PARENT
DOSE RATE DOSE
3.69069E-05 1.07066E-03
DAUGHTER
DOSE RATE
3.45426E-Q9
INDICATE PERCENT
DAUGHTER
DOSE RATE
1.02395E-11
AND DOSES (RADS)
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
3.04808E-12
DAUGHTER
DOSE
2.72793E-08
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 0.20)
8.81170E-11
ARE-
DAUGHTER
DOSE
1.56378E-16
DAUGHTER
OOSE
2.50223E-15
TOTAL
DOSE RATE
8.52554E-03
TRACT
TOTAL
DOSE RATE
2.92287E-04
TOTAL
DOSE RATE
3.93937E-08
TOTAL
DOSE RATE
1.26092E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
7.94152E-11
TOTAL
DOSE RATE
3.69069E-05
DOSE
2.52173E-05
TOTAL
DOSE
7.01590E-04
TOTAL
DOSE
1.77718E-02
TOTAL
DOSE
2.37709E-01
TOTAL
DOSE
7.77592E-02
TOTAL
DOSE ( 0.071
2.49088E-03
TOTAL
DOSE
1.18175E-06
TOTAL
DOSE
3.78265E-05
TOTAL
DOSE
1.07066E-03
-------
FOR THE PULMONARY COMPARTMENT
PARENT
DOSE RATE
9.85905E-04
FOR THE LYMPH
PARENT
DOSE RATE
1.68179E-02
FOR THE LYMPH
PARENT
DOSE RATE
1.32539E-02
PARENT
DOSE
2.7630SE-02
DAUGHTER
DOSE RATE
1.62320E-10
DAUGHTER
DOSE
4.22785E-09
TOTAL
DOSE RATE
9.85905E-04
NODES. TRANSMITTED FRACTION
PARENT
DOSE
4,052 82E-01
DAUGHTER
DOSE RATE
8.27811E-09
DAUGHTER
DOSE
1.73193E-07
TOTAL
DOSE RATE
1.68179E-02
NODES* RETAINED FRACTION
PARENT
DOSE
1.86658E-01
FOR THE REFERENCE ORGAN, PARENTHESES
PARENT
DOSE RATF
4.47541F.-04
PARENT
DOSE 1 0.06)
6.21106E-03
AT TIME 40.00 YEARS, DOSE RATES (RADS/YR)
DAUGHTER
DOSE RATE
5.78689E-09
INDICATE PERCENT
DAUGHTER
DOSE RATE
1.54289E-11
AND DOSES (RADS)
DAUGHTER
DOSE
7.34712E-08
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 0.15)
2.17215E-10
ARE-
TOTAL
DOSE RATE
1.32539E-02
TRACT
TOTAL
DOSE RATE
4.47541E-04
FOR THE NASOPHYRINGIAL COMPARTMENT
PARENT
DOSE RATE
3.93937E-08
PARENT
DOSE
1.5 7569^-06
f
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE
2.08510E-16
TOTAL
DOSE RATE
3.93937E-08
FOR -THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
1.26092F-06
PARENT
DOSE
5.04357E-05
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
3.69069E-05
PARENT
DOSE
1.43973E-03
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
3.04809E-12
DAUGHTER
DOSE
3.33635E-15
TOTAL
DOSE RATE
U26092E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
1.09896E-10
TOTAL
DOSE RATE
3.69069E-05
FOR THE PULMONARY COMPARTMENT
PARENT
DOSE RATE
9.85905E-04
PARENT
DOSE
3.74898E-02
DAUGHTER
DOSE RATE
1.62321E-10
DAUGHTER
DOSE
5.85105E-09
TOTAL
DOSE RATE
9.85905E-04
TOTAL
DOSE
2.76308E-02
TOTAL
DOSE
4.05282E-01
TOTAL
DOSE
1.86658E-01
TOTAL
DOSE I 0.06)
6.21106E-03
TOTAL
DOSE
1.57569E-06
TOTAL
DOSE
5.04357E-05
TOTAL
DOSE
1.43973E-03
TOTAL
DOSE
3.74898E-02
FOR THE LYMPH NODES, TRANSMITTED FRACTION
-------
PARENT
DOSE RATE
1.68336E-02
FOR THF. LYMPH
PARENT
DOSE RATE
1.79810E-02
PARENT
DOSE
5.73569E-01
DAUGHTER
DOSE RATE
8.32140E-09
DAUGHTER
DOSE
2.56265E-07
TOTAL
DOSE RATE
1.68336E-02
NOOESt RETAINED FRACTION
PARENT
DOSE
3.42834E-01
FOR THE REFERENCE ORGAN, PARENTHESES
PARE.NT
DOSE RATE
5.78664E-04
AT TIME 50.00 YEARS
PARENT
DOSE ( 0.06)
1.13609E-02
, DOSE RATES (RADS/YR)
DAUGHTER
DOSE RATE
8.12620E-09
INDICATE PERCENT
DAUGHTER
DOSE RATE
1.97863E-11
AND DOSES (RADS)
DAUGHTER
DOSE
1.43036E-07
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 0.121
3.93923E-10
ARE--
TOTAL
DOSE RATE
1.79810E-02
TRACT
TOTAL
DOSE RATE
5.78664E-04
FOR THE NASOPHYRINGIAL COMPARTMENT
PARENT
DOSE RATE
3.93937E-08
PARENT
DOSE
1.96962F-06
DAUGHTER
DOSE RATE
5.21315E-18
OAUGHTER
DOSE
2.60641E-16
TOTAL
DOSE RATE
3.9393 7E-08
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
1.26092E-06
PARENT
DOSE
6.30449E-05
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
3.69069E-05
PARENT
DOSE
1.80880E-03
DAUGHTER
DOSE RATE
8.34120E-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
3.04809E-12
DAUGHTER
DOSE
4.17046E-15
TOTAL
DOSE RATE
1.26092E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
l.*0377E-IO
TOTAL
DOSE RATE
3.69069E-05
FOR THE PULMONARY COMPARTMENT
PARENT
DOSE RATE
9.85905E-04
FOR THE LYMPH
PARENT
DOSE RATE
1.68349E-02
FOR THE LYMPH
PARENT
DOSE RATE
2.27068E-02
PARENT
DOSE
4.73489E-02
DAUGHTER
DOSE RATE
1.62321E-10
DAUGHTER
DOSE
7.47426E-09
TOTAL
DOSE RATE
9.85905E-04
NODES, TRANSMITTED FRACTION
PARENT
DOSE
7.4191AE-01
DAUGHTER
DOSE RATE
8.32590E-09
DAUGHTER
DOSE
3.39510E-07
TOTAL
DOSE RATE
1.68349E-02
NODES, RETAINED FRACTION
PARENT
DOSE
5.46274E-01
DAUGHTER
DOSE RATE
1.04661E-08
DAUGHTER
DOSE
2.35997E-07
TOTAL
DOSE RATE
2.27068E-02
TOTAL
DOSE
5.73570E-01
TOTAL
DOSE
3.42834E-01
TOTAL
DOSE ( 0.06)
1.13609E-02
TOTAL
DOSE
1.96962E-06
TOTAL
DOSE
6.30449E-05
TOTAL
DOSE
1.80880E-03
TOTAL
DOSE
4.73489E-02
TOTAL
DOSE
7.41914E-01
TOTAL
OOSE
5.46274E-01
-------
FOR THE REFERENCE ORGAN, PARENTHESES INDICATE PERCENT OF TOTAL DOSE VIA GI TRACT
PARENT
DOSE RATE
6.88946E-04
PARENT
DOSE 1 0.06)
1.77149E-02
I HE 7.0.00 YEARS, DOSE RATES IRADS/YRI
DAUGHTER
DOSE RATE
2.34480E-11
AND DOSES (RADS)
DAUGHTER
DOSE ( 0.111
6.10624E-10
ARE--
TOTAL
DOSE RATE
6.88946E-04
FOR THE NASOPHYR1NGIAL COMPARTMENT
PARENT
DOSE RATE
3.9393TE-08
PARENT
DOSE
2. 7575 OE- 06
DAUGHTER
DOSE RATE
5.21315E-18
DAUGHTER
DOSE
3.64904E-16
TOTAL
DOSE RATE
3.93937E-08
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
1. 26092 E-06
PARENT
DOSE
8.82632E-05
FOR THE TRACHEOBRONCHIAL COMPARTMENT
PARENT
DOSE RATE
3.69069E-05
FOR THE PULMONARY
PARENT
DOSE RATE
9. 859056-04
PARENT
DOSE
2.54693E-03
COMPARTMENT
PARENT
DOSE
6.70670E-02
DAUGHTER
DOSE RATE
8.341ZOE-17
DUE TO CLEARANCE
DAUGHTER
DOSE RATE
3.04809E-12
DAUGHTER
DOSE RATE
1.62321E-10
DAUGHTER
DOSE
5.83870E-15
TOTAL
DOSE RATE
1.26092E-06
FROM PULMONARY COMPARTMENT
DAUGHTER
DOSE
2.01339E-10
DAUGHTER
DOSE
1.07207E-08
TOTAL
DOSE RATE
3.69069E-05
TOTAL
OOSE RATE
9.85905E-04
FOR THE LYMPH NODES, TRANSMITTED FRACTION
PARENT
DOSE RATE
1.68350E-02
PARENT
DOSE
1.07861E+00
DAUGHTER
DOSE RATE
8.32639E-09
DAUGHTER
DOSE
5.06036E-07
TOTAL
DOSE RATE
1.68350E-02
FOR THE LYMPH NODES, RETAINED FRACTION
PARENT
DOSE RATE
3.21542E-02
FOR THE REFERENCE
PARENT
DOSE RATE
8.59609E-04
PARENT
DOSE
1.09489E+00
ORGAN, PARENTHESES
PARENT
DOSE ( 0.061
3.32990E-02
DAUGHTER
DOSE RATE
1. 51458E-08
INDICATE PERCENT
DAUGHTER
DOSE RATE
2.91139E-U
DAUGHTER
DOSE
4.92116E-07
OF TOTAL DOSE VIA GI
DAUGHTER
DOSE ( 0.10)
1.13951E-09
TOTAL
DOSE RATE
3.21543E-02
TRACT
TOTAL
DOSE RATE
8.59609E-04
TOTAL
DOSE ( 0.06)
1.77149E-02
TOTAL
DOSE
2.75750E-06
TOTAL
DOSE
8.82632E-05
TOTAL
DOSE
2.54693E-03
TOTAL
DOSE
6.70670E-02
TOTAL
OOSE
1.07861E+00
TOTAL
DOSE
1.09489E+00
TOTAL
DOSE I 0.06)
3.32990E-02
END OF CASE
-------
FORTRAN IV G LEVEL 21
MAIN
APPENDIX III
DATE = 77039
15/17/51
PAGE 0001
0001
0002
0003
0004
0005
0006
0007
0008
0009
0010
0011
0012
0013
0014
0015
0016
0017
0018
0019
0020
0021
0022
0023
0024
0025
0026
0027
0028
0029
0030
0031
0032
0033
0034
0035
0036
C
C
C
C
C
C
C
C
C
C
C
REAL IA.IC
REAL * 8 LTPl,LTDl,LRP,LBP,LRD,LBD,tTP2,LTD2,LTP3,LTD3,
1 NPT1,NPT2»MPT3,NDT1,NDT2,NDT3,IPT1,IPT2,IPT3,IDT1,IDT2,IOT3
REAL * 8 P12,P13,P23,P21,P31,P32,P1D1,P1D2,P1D3,P2D1,
1 P2D2,P2D3,P3Dl,P3D2fP3D3,DlPl,D2P2,D3Pl,01P2,D3P2,DlP3,02P3,
2 D3P3,D2P1,012,013,021,023,031,032
REAL * 8 B1D,B2D,B3D,A2D,A3D,A4D,D1D,02D,03D,C2D,C3D,C4D
REAL * 8 BE1,BE2,BE3,BE4,AL2,AL3,AL4,AL5,B1,B2,B3,B4,A2,A3,A4,A5,
lDl,D2tD3.D4,C2,C3,C4,C5
REAL * 8 NPT2R,NDT2R,IPT2R,IDT2R,B1DR,B2DR,B3DR,A2DR,A3DR,A4DR,
1D1DR,D2DR,D3DR,C2DR,C3DR,C4DR,P12R,P21R
REAL * 8 LB,Z,ODP,DPLN2
DIMENSION DX(10),LB(15),FD(15),ORGMU5),HOLL(20),TIN(25)
THIS PROGRAM REPRESENTS THE ICRP TGLD LUNG MODEL MODIFIED BY ICRP-19,
IT USES SUB-CHAINS CONSISTING OF 1. A LUNG COMPARTMENT (A-HI,
2. FOR A-G, THE REFERENCE ORGAN. FOR H, THE LYMPH NODES.
3. FOR H ONLY, THE REFERENCE ORGAN.
THE PROGRAM ALLOWS THE PARENT AND ONE DAUGHTER TO BE CALCULATED.
CARDS WITH A CTB WERE ADDED TO GET P/T-B CLEARANCE DOSE.
CARDS WITH AN R WERE ADDED TO GET LYMPH NODE RETENTION DOSE.
50 READ (5,155,END=800) IHOLL(K),K=1,20)
275 FORMATC3I10)
100 READ 15,275) NTT,IHG,1FLAG
155 FORMAT(20A4)
WRITE(6,255) IHOLUK) ,K=l,20)
255 FORMAT!1H1,24X,20A4///)
355 FORMAT(6E12.5)
READ (5,355) LRP,LBP,F1PR,F2PPR,EPSPL,EPSPR
READ (5,355) LRD,LBD,F1DR,F2PDR,EPSDL,EPSDR
READ (5,355) (TIN(I),I«1,NTT)
READ (5,355) IA,IC,UTA3,UTA4,UTA5,ORGMR
WRITE(6,305)
305 FORMATdH ,12X,5HACUTE, 15X,7HCHRONIC, 14X,5HN - P,15X,5HT - B,17X,1
1HP,14X,9HREFERENCE/9X,11HINTAKE (CI) ,9X ,14HINTAKE (CI/YR I,8X, 10HOE
2POSITION,10X,10HDEPOSITION,10X,10HDEPOSITION,7X,1
-------
FORTRAN IV G LEVEL 21
IAIN
DATE = 77039
15/17/51
PAGE 0002
0037
0038
0039
0040
0041
0042
0043
0044
0045
0046
0047
0048
0049
0050
0051
0052
0053
0054
0055
0056
0057
0058
0059
0060
0061
0062
0063
0064
0065
0066
0067
0068
0069
0070
0071
0072
0073
0074
0075
0076
0077
0078
0079
0080
0081
0082
0083
0084
0085
0086
0087
0088
0089
0090
DX(5)=UTA4
OX(6)=UTA5
DX(71=UTA5
DX(8)=UTA5
LB(1)=2.740-5
LBC2)=2.740-5
LB(3)=1.37D+0
LB(4)=l.lD-3
LB<5)=5.5D-4
LB<6)=2.7D-3
LB(7i=1.370+0
LB(8)=1.370+0
LB(9)=2.74D+0
FD(1)=0.010+0
FD(2)=0.010+0
FD(3)=0.05D+0
FD(4I=0.99D+0
F0(5)=0.990+3
FD(6)=0.4D+0
FD(7)=0.4D+0
FD(8)=0.150+0
FD(9)=0.90+0
ORGM(1)=32.0
ORGM(2)=40.0
ORGM<3)=570.0
ORGM«4>=32.0
ORGM<5)=40.0
ORGM(6)=570.0
ORGM«7)=570.0
ORGM(8)=570.0
ORGM(9)=15.0
TEFF = 0.0039
OMTB=ORGM(2)
ODP=1.0D+0
OPLN2=6.930-1
CON=1.87E+10
LRP=DPLN2/LRP
LBP=OPLN2/LBP
LRD=DPLN2/LRD
LBD=OPLN2/LBD
DO 400 K=l,9
400 LB(K)=DPLN2/LB(K)
IF(IHG.GT.O) rfRITE«6,360)
IF(IHG.LT.O) MRITE(6,365)
360 FDRMATtlH' ,40X,51HTHE FOLLOWING CASE IS FOR UPTA
-------
FORTRAN IV G LEVEL 21
MAIN
DATE = 77039
15/17/51
PAGE 0003
0091
0092
0093
0094
0095
0096
0097
0098
0099
0100
0101
0102
0103
0104
0105
0106
0107
0108
0109
0110
0111
0112
0113
0114
0115
0116
0117
0118
0119
0120
0121
0122
Oi23
0124
0125
0126
0127
0128
0129
0130
0131
0132
0133
0134
0135
0136
0137
0138
0139
0140
0141
0142
0143
0144
ORPTB=0.0
DRDTB=0.0
DRPP=0.0
DRDP=0.0
DRPL=0.0
DRDL=0.0
DRPRO=0.0
DRDRO=0.0
DPNP=0.0
DDNP=0.0
OPTB=0.0
ODTB=0.0
DPP=0.0
DDP=0.0
DPL=0.0
DDL=0.0
DPRO=0.0
DORO=0.0
DPGIT=0.0
DOGIT=0.0
QLPCTB=0.0
QUPCTB=0.0
QLDCTB=0.0
QUDCTB=0.0
JT=8
IF(IHG.LT.O) JT=1
C START EACH SUB-COMPARTMENT CHAIN
DO 600 J=1,JT
C DXU) SET OUTSIDE LOOP.
C WHOLE PROGRAM PREDICATED ON PARENT AND DAUGHTER BEING CLASS Y.
DK=OX(J)
LTP1=L*RP+LBU)
IFUHG.LT.O) LTP1=LRP*LBP
LTD1=LRD+LB(J*)
IF(IHG.LT.O) LTD1=LRD+LBD
LTP2 = LRP+LB
-------
FORTRAN IV G LEVEL 21
MAIN
DATE = 77039
15/17/51
PAGE 0004
0145
0146
0147
0148
0149
0150
0151
0152
0153
0154
0155
0156
0157
0158
0159
0160
0161
0162
0163
0164
0165
0166
0167
0168
0169
0170
0171
0172
0173
0174
0175
0176
0177
0178
0179
0180
0181
0182
0183
0184
0185
0186
0187
0188
0189
0190
0191
0192
0193
0194
0195
0196
0197
0198
0199
FP3=1.0
FD3=1.0
C SET F2P AND Fl FOR BLOOD AND GIT. J=lt2,3t8 ARE BLOOD ONLY.
C J=4,5t&,7 ARE BLOOD AND GIT (F2P*F1) BOTH.
IF( J.LE.3.riR. J.EQ.8) F1P=1.0
IF(J.LE.3.0R.J.EQ.8) F1D=1.0
C DO ALL PARAMETERS IN EQUATIONS.
NPT1=O.OD+0
IF GO TO 485
NDT3 =DEXP(-LT03*Z>
NDT3=O.OD+0
485 CONTINUE
I'PTl = OOP - NPTl
IPT2 = OOP - NPT2
1PT2R = OOP - NPT2R
IPT3 = OOP - NPT3
IDT1 = OOP - NDT1
IDT2 = OOP - NDT2
IDT2R = OOP - NDT2R
IDT3 = ODP - NDT3
P12 = -LTP1 * LTP2
P12R = -LTP1 * LRP
P21R = -P12R
P13 = -LTP1 * LTP3
P23 = -LTP2 * LTP3
P21 = -P12
P31 = -P13
P32 = -P23
P1D1 = -LRP*LRD
IFIIHG.LT.O) P1D1=-LTP1*LTD1
P1D2 = -LTP1 * LTD2
CYB
CTB
CTB
CTB
CTB
CTB
CTB
CTB
CTB
CTB
R
R
-------
FORTRAN IV G LEVEL 21
MAIN
DATE = 77039
15/17/51
PAGE 0005
0200
0201
0202
0203
0204
0205
0206
0207
0208
0209
0210
0211
0212
0213
0214
0215
0216
0217
0218
0219
0220
0221
0222
0223
0224
0225
0226
0227
0228
0229
0230
0231
0232
0233
0234
0235
0236
0237
0238
0239
0240
0241
0242
0243
0244
0245
0246
0247
0248
0249
0250
0251
0252
0253
P1D3 = -LTP1 + LT03
P201 = -LTP2 * LTD1
P2D2 = -LTP2+LTD2
IFU.EQ.8) P2D2 = -LRP+LRD
P2D3 = -LTP2 * LTD3
P3D1 = -LTP3 * LTD1
P3D2 = -LTP3 * LTD2
P3D3 = -LTP3*LT03
D1P1 = -P1D1
D2P1 = -P1D2
D3P1 = -P1D3
D1P2 = -P2DI
D2P2 = -P2D2
D3P2 = -P2D3
D1P3 = -P3D1
D2P3 = -P3D2
03 P3 = -P3D3
D12 = -LTD1 * LTD2
D13 = -LTD1 + LT03
021 = -D12
D23 = -'LTD2 + LTD3
031 = -D13
D32 = -023
PARENT ACTIVITY IN FIRST SUB-COMPARTMENT.
CONA = IA*DK*FL
CONC = IC*DK*FL
IFUHG.LT.O) CONA=IA*FIPR*F2PPR
IFUHG.LT.O) CONC=IC*F1PR*F2PPR
QLPAl = CONA*NPT1
QLPC1 = CONC*( IPT1/LTP1)
QUPA1 = CONAMIPT1/LTP1)
QUPC1 = CONCM ( Z /LTPl)+( IPTl/«-LTPl*LTPl) ) )
IFt J.LT.6.0R. J.5T.7) 30 TO 505
QLPCTB=QLPCTB+TEFF*LB( J ) *( OLPAH-QLPC1)
QUPCTB=QUPCTB+TEFF*LB(J )*(QJPAH-3UPC1)
5C5 CONTINUE
IFU.EQ.8) DRPCTB=CON*( EPSPL/OMTB)*QLPCTB
IFU.EQ.8) DPCTB=CON*(EPS!JL/OMTB)*QUPCTB
IF(IHG.LT.O) EPSPL=EPSPR
DRP1 = CON*(EPSPL/OMAS)*(OLPA1«-QLPC1)
DPI = CON*(EPSPL/OMAS)*)
QUPA2=CONA*(IIPTI/(LTP1*P12) ) +( IPT2/(. TP2*P21 ) ) )
QUPC2=CONC*«(Z/(LTP1*LTP2) J+l I PT1/ l-LT P1*LTP1*P12 ) )+( IPT2/ t-LTP2*L
1TP2*P21) ) )
EPV=EPSPR
IFU.EQ.8) EPV = EPSPL
IF(J.NE.S) GO TO 558
COARET=(CONA/FP2)*t 1.0-FP2)
COCRET= (CONC/ FP2)* ( 1.0-FP2 )
QLPA2R=CnARET*{ (NPT1/P12R) +( NPT2R /P211 ) )
OLPC2R=COCRET*{ (HOP/ (LTP1*LRP ) ) + (NPTl/ (-LTPl*P12:l ) )+( NPT2R /( -LRP*P
CTB
CTB
CTB
CTB
-------
FORTRAN IV 6 LFVFL 21
MAIN
DATE
77039
15/17/51
PAGE 0006
0254
0255
0256
0257
0258
0259
0260
0261
0262
0263
0264
0265
0266
0267
0268
0269
0270
0271
0272
0273
0274
0275
0276
0277
0278
0279
0280
0281
0282
0283
0284
0285
0286
0287
0288
0289
0290
0291
0292
0293
0294
0295
0296
0297
0298
121RM)
QUPA2R=COARET*(HPT1/(LTP1*P12RM + UPT2R/(LRP*P21R)))
QUPC2R=COCRET*( (Z/(LTP1*LRP) l-MIPTl/(-LTPl*LTPl*P12R))*UPT2R/<-LR
1P*LRP*P21R))»
DRP2R=CON*(EPSPL/TMAS)*(QLPA2R+QLPC2R)
DP2R=CON*(EPSPL/TMAS)*(QUPA2RtQUPC2R)
558 CONTINUE
DRP2=CON*(EPtf/TMAS)*(QLPA2+QLPC2J
DP2=CON*(EPV/TMAS)*(QUPA2+QUPC2)
THIRD SUB-COMPARTMENT. ONLY USE IF LYMPH NODES IN CHAIN.
0.0
0
0
0
= 0.
0.
0.
QLPA3
QLPC3
QUPA3
QUPC3
DRP3=0.0
DP3=0.0
IFU.NE.8) GO TO 333
CONA=CONA*LB(J*1)*FIP*F2PPR
CONC=CONC*LB(J+1)*F1P*F2PPR
QLPA3=CONA*(tNPTl/
-------
FORTRAN IV G LEVEL 21
MAIM
DATE = 77039
15/17/51
PAGE 0007
0299
0300
0301
0302
0303
0304
0305
0306
0307
0308
0309
0310
0311
0312
0313
0314
0315
0316
0317
0318
0319
0320
0321
0322
0323
0324
0325
0326
0327
0328
0329
0330
0331
0332
0333
0334
0335
0336
0337
0338
0339
0340
0341
0342
0343
0344
0345
0346
0347
0348
0349
0350
0351
B1D=P12*P1D2
•B2D=P21*P202
B3D=D2P1*D2P2
A20=-LTP1*B1D
A3D=-LTP2*B2D
A40=-LTD2*B3D
D1D=P1D1*P1D2
D2D=D1P1*D12
D3D=D2Pl*D21
C2D=-LTP1*D1D
C3D=-LTD1*D2D
C4D=-LT02*D3D
IFU.NE.8) 63 TO 337 R
B1DR=P12*(-LTP1*LRD) R
62DR=P21*(-LTP2*LRD) R
B3DR=C-LRD+LTP1)*(-LRD+LTP2) R
A2DR=-LTP1*B1DR R
A3DR=-LTP2*B2DR R
A40R=-LRD*B3DR R
D1DR=P101*(-LTP1*LRD) R
D2DR=D1P1*(-LT01«-LRO) R
D3DR={-LRD+LTP1)*(-LR3VLTD1J R
C2DR=-LTP1*D1DR R
C30R=-LTD1*D2DR *
C4DR=-LRD*D30R R
337 CONTINUE R
QLA=A*«ODP/+(IPT2/A3DR)+(IDT2R/A4DR)) R
-------
FORTRAN IV 6 LEVEL 21
MAIN
DATE = 77039
15/17/51
PAGE 0008
0352 QUCR=CR*UZ/(LTPl*LTDl*LRD)KUPTl/tLTPl*C2DR))+UDTl/ILTDl*C3DRM
H-UDT2R/(LRD*C40R))i
0353 QUDR=DR*(
-------
FDRTRAN IV G LEVEL 21
IAIN
DATE = 77039
15/17/51
PAGE 0009
0407
0*08
0409
0410
0'*U
0412
0413
0414
0415
0416
0417
0418
0419
0420
0421
0422
0423
0424
0425
0426
0427
0428
0429
0430
0431
0432
0433
0434
0435
0436
0437
0438
0439
0440
0441
0442
0443
0444
0445
0446
0447
0448
0449
0450
0451
0452
C3=-LTD1*D2
C4=-LTD2*D3
C5=-LT03*D4
QLAL=AL*((OOP/(LTP1*LTP2*LTP3*LT03))+(NPT1/AL2)+(NPT2/AL3)+(NPT3/A
1L4K(NDT3/AL5))
QLBE=BE*t (NPTl/BFl)t(NPT2/BE2) + (NPT3/8E3)<-(NOT3/BE4))
QLAP=AP*((OOP/(LTPl*LTP2*LTD2*LTD3)) + ( NPT1/A2I*IMPT2/A3)*( NOT2/A4I
H-INDT3/A5J)
QLBP=BP*{ (NPTl/fUU(NPT2/B2K(NDT2/B3H-(NDT3/P4J )
QLCP=CP*((OOP/(LTPl*LTDl*LT02*Ln3)) + (NPT1/C2)* IMDT1/C3)+INDT2/C4)
1+INOT3J)
QLDP=DP*((NPT1/D1)*{NDT1/D2)*(NDT2/D3I+(MDT3/D4))
QLDA3=QLBE+QLBP«-QLDP
QLDC3=QLAL+QLAP«-QLCP
QUAL=AL*((Z/(LTP1*LTP2*LTP3*LTD3))t(IPT1/(LTP1*AL2))*(IPT2/(LTP2*A
1L3)J*(IPT3/(LTP3*AL4)) + ( IDT3/(LTD3*AL5)))
QUBE = BE*(UPTl/UTPl*aEl)) + lIPT2/DRORO>DRD3
,EQ,
.EQ,
.EQ,
.EQ,
.LT,
.FQ
IF(J
IF(J
IF(J
IF(J
IF(J
IFU
IF1J.EQ
IF(J.EQ
IFIJ.EQ
IF(J
IFU
IFU
IFU
IFU
IFU
IFU
IFU
IFU.EQ.8)
IFU.EQ.8)
OR.
OR.
OR.
OR.
OR.
.EQ.
.EQ.
.EQ.
.E3.
,GE,
4)
4)
51
5)
6)
DPNP=OPNP-fDPl
DDNP=DDNP+DD1
DPTB=DPTB*DP1
DOTB=ODTflfDDl
OPP=DPP*OP1
DDP=DDP*ODl
EQ.
EQ.
EQ.
EQ.3.0R.J.GP.6)
LT.8) DPRO=OPRO-«-DP2
LT.8J ODRO=DORO+DD2
GE.4.AND.J.LE.7) DPGIT=DPGIT+OP2
GE.4.AND.J.LE.7) DnGIT=DOGIT+DD2
DPL=9P2
DDL=002
-------
FORTRAN IV G LEVEL 21
MAIN
DATE = 77039
15/17/51
PAGE 0010
0453
0454
0455
0456
0457
0458
0459
0460
0461
0462
0463
0464
0465
0466
0467
0468
0469
0470
0471
0472
0473
0474
0475
0476
0477
0478
0479
0480
0481
0482
0483
0484
0485
0486
0487
0488
0489
0490
0491
0492
0493
0494
0495
0496
0497
0498
0499
0500
0501
0502
C
C
C
IFU.EQ.8) DPRO=DPRODP3
IFU.E0.81 D3RO=DDRO«-DD3
600 CONTINUE
ALL CTB AND RET L DR AND D CALCULATED AB INITIO EACH J IFF J.E0.8.
DRTNP = DRPNP*DRDNP ,
DRTTB=DRPTB+DRDTB
DRTCTB=DRPCTB*DRDCTB
DRTP=DRPP+DRDP
DRTL=DRPL+DRDL
DRT2R=DRP2R*DRD2R
DRTRO=DRPRO+DRDRO
DTNP=DPNP+DDNP
DTTB=DPTB*DDTB
DTCTB=DPCTB*DDCTB
OTP=DPP+DDP
DTL=DPL«-DDL
DT2R=DP2R+DD2R
DTRO=DPRO+DDRO
IF(IHG.LT.O) 50 TO 666
DTGIT=DPGIT+DDGIT
DPRAT=1.0E«-2*(DPGIT/DPRO)
DDRAT=1.0E+2*tDDGIT/DDR3)
DTRAT=1.0E+2*(DTGIT/DTRO)
IF( IFLAG.LT.O) GO TO 660
HRITE(6,615)
615 FDRMATdH tlOX,34HFOR THF NASOPHVRINGIAL COMPARTMENT/)
WRITE(6,655) DRPNP,DPNP,ORDNP,DDNP,DRTNP,DTNP
WRITE(6,625)
625 FORMAT!IH ,10X,36HFO* THE TRACHEOBRONCHIAL COMPARTMENT/)
WRITE(6,655) DRPTB,DPTB,DRDTB,DDTB,ORTTB,DTTB
WRITF(6,627)
627 FORMATIIH ilOX,8aHFOR THE TRACHEOBRONCHIAL COMPARTMENT DUE TO CLHA
1RANCE FROM PULMONARY COMPARTMENT/)
MRITE(6,655) DRPCTB,DPCTB,DRDCTB,DDCTB.DRTCTB.DTCTB
MRITE(6,635)
63*5 FORMATIIH ,1DX,29HFOR THE PULMONARY COMPARTMENT/)
" WRITE(6,655) DRPP,DPP,DROP,OOP,DRTP,DTP
WRITE(6,645)
645 FORMATC1H ,13K,41HFOR THE LYMPH NODES, TRANSMITTED FRACTION/1
HRITF(6,655) DRPL,DPL,DRnL,DDL,DRTL,DTL
WRITE(6,647)
647 FORMATdH ,10X,38HFO^ THE LYMPH N03ES, RETAINED FRACTION/)
WRITE(6,655) DRP2R,OP2R,DRD2R,DD2R,DPT2R.DT2R
660 CONTINUE
WRITE(6,665)
665 FORMATdH ,1JX,80HFOR THF REFERENCE ORGAN, PARENTHESES INDICATE PE
1RCENT OF TOTAL DOSE VIA GI TRACT/)
WRITE (6,657) DP RAT ,DDRAT ,DTRAT, DRPRO,OPRO, DRDRO, DDRD, DRTROOTRO
IF( IHG.GT.O) GO TO 700
666 WRfTE(6,670)
670 FORMATdH ,10X,23HFO* THE REFERENCE ORGAN)
WR'ITE(6,655) DRPNP,DPMP,DRDNP,DDNP,DRTNP,DTNP
655 FORMATdH ,12K ,6HPARENT,13X.6HPARENT,13X,8HOAJGHTER,12X,8HDAUGHTER
1,14X,5HTOTAL,14X,5HTOTAL/11X,10HDOSE RATE,12X,4HOOSE,13X,10HDOSE
2 RATF,13X,4HDOSE,14X,10HDOSE RATE,11X,4HDOSE/9X,1PE12.5,1P5E20.5/
-------
f
U
§
FORTRAN IV G LEVEL 21 MAIN DATE = 77039 15/17/51 PAGE 0011
0503 657 FORMAT!1H ,12Xt6HPARENT , 13X,6HPARENTfl3X,8HDAUGHTER,12X.8HDAUGHTER
1,14X,5HTOTAL,14X,5HTOTAL/11X,10HOOSE RATE,8X,6HDOSE I,F5 .2,1H),9X
2.10HDOSE RATE,9Xt6HDOSE I,F5.2,1H) ,10X,10HDOSE RATE ,9X,6HDOSE (,
3F5.2tlHJ/9X,lPE12.5,1P5E20.5//J
0504 700 CONTINUE
0505 HRITE(6,755)
0506 755 FORMATI1H ,63X,11HEND OF CASE)
0507 GO TO 50
0508 800 CALL EXIT
0509 STOP
0510 END
------- |